The world's first weekly insulin preparation has encountered setbacks in the United States, and the FDA requires additional information, with no hope of approval this year
我放心你带套猛
发表于 2024-7-12 14:02:06
217
0
0
The world's first weekly insulin preparation has encountered setbacks in its launch in the United States.
On July 10, Denmark time, Novo Nordisk announced that it had received a complete response letter (CRL) from the United States Food and Drug Administration (FDA), which covered the application for biological product licensing (BLA) for the treatment of adult diabetes with insulin, a weekly preparation of basic insulin (English name: Insulin icodec).
On June 24 of this year, insulin injection (Chinese trade name: Novosi) was officially approved for marketing in China to treat adult type 2 diabetes. novo nordisk
Novo Nordisk said that the US FDA requires it to provide detailed information about the production process and the indications for type 1 diabetes. Novo Nordisk is evaluating the relevant content and working closely with the US FDA to meet the requirements, but it is expected that these requirements will not be met this year.
With regard to the setback of Iko insulin in the United States, Novo Nordisk responded to Time Finance and said: "Novo Nordisk will continue to be committed to fulfilling its commitment to patients with diabetes, and will cooperate with the US FDA to solve possible problems and determine the follow-up steps required to complete the approval."
The half-life of Yike insulin is as long as 196 hours (about 7 days), which means that within a one week dosing interval, the hypoglycemic effect of this product is evenly distributed. At clinically relevant doses, the hypoglycemic effect time can cover one week.
In April 2023, Novo Nordisk submitted a marketing application for Ecoinsulin to the US FDA. In May of this year, the Endocrine and Metabolic Medicine Advisory Committee of the US FDA held a meeting, where an independent scientific expert group discussed the specific situation of Yike insulin. At this meeting, the US FDA believed that the existing data could not support the use of this drug in patients with type 1 diabetes.
Novo Nordisk told Time Finance that the relevant suggestions discussed above are only about the treatment of type 1 diabetes. The FDA did not seek the opinions of the committee on the use of Eko insulin in adult type 2 diabetes at this meeting.
Although the approval of Yike insulin in the United States has encountered setbacks, this product has already been approved in multiple regions around the world, including the European Union, Switzerland, Canada, and Australia.
In March 2024, the Commission for Human Medicines (CHMP) of the European Drug Administration approved the use of Eko insulin injection (European listed brand name: Awiqli) for the treatment of adult diabetes. CHMP believes that this product achieves better blood glucose reduction effect and better blood glucose range retention time in patients with type 2 diabetes compared with daily basic insulin.
In terms of the Chinese market, on June 24 of this year, Iacovin injection (Chinese trade name: Novosi) was officially approved for listing in China for the treatment of adult type 2 diabetes, but the specific time and price of commercialization were not announced yet.
The tenth version of the IDF diabetes map shows that the total number of adult diabetes patients in China has reached 140 million, ranking first in the world. Among them, type 2 diabetes patients account for the majority, but only 16.5% of Chinese adult diabetes patients reach the standard of blood glucose control. Insulin is the best choice for most patients with diabetes. However, in the use of insulin, patients often have low compliance. Many patients are unwilling to take injections or inject drugs many times a day. Therefore, the approval of long-acting insulin is more convenient for patients.
Novo Nordisk's old rival, Eli Lilly, is also laying out insulin weekly preparations. In May of this year, Eli Lilly disclosed the research progress of its insulin weekly preparation Efsitora. According to data from two Phase 3 clinical trials, QWINT-2 and QWINT-4, Efsitora showed a comparable reduction in HbA1c (glycated hemoglobin) compared to the most commonly used daily basal insulin globally.
Efsitora is a weekly injection of basal insulin, a fusion protein that combines a novel single chain insulin variant with a human IgG2 Fc domain. It is designed for subcutaneous administration once a week, with a low peak to valley ratio, which may provide more stable blood glucose levels (less blood glucose fluctuations) within a week. Efstora is in the phase 3 development stage for adult type 1 and type 2 diabetes patients.
In terms of domestic pharmaceutical companies, Ganli Pharmaceutical (603087. SH) launched a phase II clinical trial of its self-developed product GZR4 in China in September last year, and completed the first subject administration. This product is a weekly super long acting insulin preparation that is injected subcutaneously once a week, and its indication is diabetes.
At the end of June this year, Ganli Pharmaceutical announced the latest progress of this product at the 84th Scientific Conference of the American diabetes Association (ADA) in 2024. Ganli Pharmaceutical stated that compared with Yike Insulin Injection, GZR4 has a significantly increased affinity for human serum albumin (HSA) and a significantly decreased affinity for insulin receptors. After binding with albumin to form a complex, GZR4 can still maintain the activity of activating insulin receptors. In the study of animal models of diabetes, the hypoglycemic effect of GZR4 is 2-3 times as much as that of Yike insulin injection.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Novo Nordisk invests approximately 4 billion RMB in the expansion project of sterile preparations in Tianjin
- Novo Nordisk invests approximately 4 billion RMB in the expansion project of sterile preparations in Tianjin
- Novo Nordisk invests approximately 4 billion RMB in the expansion project of sterile preparations in Tianjin
- Novo Nordisk invests approximately 4 billion yuan in the expansion project of sterile preparations in Tianjin
- 4 billion yuan! Novo Nordisk launches aseptic formulation expansion project
- European regulators recommend approval of insulin once a week for treatment of diabetes
- Novo Nordisk Ultra Long acting Insulin Global First Batch Expected Within Two Months
- Lilly Ultra Long acting Insulin Phase III Clinical Success
- Before the United States! What is the safety and efficacy of the world's first weekly insulin injection approved in China
- Collaboration is becoming increasingly close, with hundreds of engineers from Volkswagen settling in at Xiaopeng Motors headquarters. The first collaborative model is expected to be mass-produced within 24 months
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 昨天 16:36
- 支持
- 反对
- 回复
- 收藏
-
アリババは、26億5000万ドルのドル建て優先無担保手形と170億元の人民元建て優先無担保手形の定価を発表した。ドル債の発行は2024年11月26日に終了する予定です。人民元債券の発行は2024年11月28日に終了する予定だ ...
- SOGO
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 前天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 前天 14:29
- 支持
- 反对
- 回复
- 收藏